Evopoint Biosciences Inc.
Clinical trials sponsored by Evopoint Biosciences Inc., explained in plain language.
-
New hope for rare blood cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests a new tablet, XNW5004, against another drug (Chidamide) in people with a rare blood cancer called peripheral T-cell lymphoma that has come back or not responded to prior treatment. About 120 adults aged 18-70 will participate. The main goal is to see if XNW5004 c…
Phase: PHASE3 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated May 26, 2026 08:44 UTC
-
New hope for hard-to-treat cancers? first human trial of XNW28012 begins
Disease control Recruiting nowThis study tests a new drug called XNW28012 in people with advanced solid tumors (like pancreatic, ovarian, or cervical cancer) who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. About 350 participants will take part in tw…
Phase: PHASE1, PHASE2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated May 26, 2026 08:41 UTC
-
New hope for Tough-to-Treat lymphoma: experimental pill shows promise
Disease control Recruiting nowThis study tests an experimental drug called XNW5004 in 65 adults with follicular lymphoma (a slow-growing blood cancer) that has returned or stopped responding after at least three prior treatments. Participants take the drug twice daily for 28-day cycles. Researchers will measu…
Phase: PHASE2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC